Our drug research and development pipeline
Our product pipeline reflects our commitment to developing innovative products that help diagnose or treat gastrointestinal disorders. Salix focuses on innovative gastrointestinal products and investigating currently marketed products for new indications. This page features information on the compounds currently in our pipeline. Information on this page is current as of 11/25/2014.
PHASE 2 PHASE 3
MDP (Multi-Dose Pen)
|Opioid induced constipation (OIC) in advanced illness|
|Methylnaltrexone Bromide |
|OIC in chronic non-cancer pain|
for the treatment of IBS-D*
|Irritable bowel syndrome with diarrhea|
(Soluble Solid Dispersion)
|Prevention of complications with early decompensated liver cirrhosis|
|Investigational Bowel Purgative||Bowel prep for preparation of colonoscopy and other abdominal procedures||In development|
2014 Drug Approvals and press release date; Budesonide Foam (08Oct2014), Methylnaltrexone Bromide SC Injection (29Sept2014), Ruconest (17Jul2014)
*The resubmission of sNDA for IBS-D is considered a class 2 response to the FDA's March 7, 2011 action letter and has been assigned a user fee goal date of February 28, 2015.